Table 3 Susceptibilities to key agents among the Proteus mirabilis isolates with and without ESBL or AmpC β-lactamases genes
Antimicrobial agenta | Susceptibility (%) | |||
|---|---|---|---|---|
ESBL(+)/AmpC(+) | ESBL(+)/AmpC(-) | ESBL(-)/AmpC(+) | Non-ESBL phenotype & ESBL(-)/AmpC(-) | |
(n = 7) | (n = 88) | (n = 47) | (n = 1015) | |
Amikacin | 57.1 | 28.4 | 40.4 | 97.8 |
Aztreonam | 100 | 94.3 | 97.9 | 99.8 |
Cefepime (S/SDD)b | 42.85/42.85 | 29.5/38.6 | 91.5/6.4 | 99.9/0.1 |
Cefotaxime | 0 | 0 | 0 | 99.7 |
Ceftazidime | 71.4 | 94.3 | 53.2 | 99.7 |
Ciprofloxacin | 42.9 | 6.8 | 34.0 | 75.9 |
Ertapenem | 100 (n = 4) | 100 (n = 26) | 100 (n = 26) | 99.7 (n = 315) |
Imipenem_2009 | 100 | 100 | 100 | 99.9 |
Imipenem | 42.9 | 45.5 | 66.0 | 51.7 |